What Is Aligos Therapeutics, Inc. (ALGS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Aligos Therapeutics, Inc.'s intrinsic value is estimated at $8.40, presenting a divided outlook at the current price of $5.77. With an average implied return of +45.7% across a split 4–4 (bull–bear) consensus, the model spread of +298.3% underscores analytical uncertainty. Notably, ML-RIV sees the most upside at +252.8% (fair value: $20.36), while Bayesian DCF is the most conservative at -45.5% ($3.14). The spread between these extremes — +298.3% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About ALGS?
10 of 13 models are currently active for ALGS. Of these, 4 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates ALGS's intrinsic value at $3.14, implying -45.5% downside from the current price. See which stocks rank higher →
How Does ALGS Rank in Biotechnology?
Among 76 Biotechnology stocks, ALGS ranks #63 by Quality of Company score. CirclFi's QOC score of 4.1/10 evaluates 32 fundamental signals. A score of 4.1 reflects mixed fundamentals.
See all Most Undervalued Biotechnology Stocks →
As a life sciences company, Aligos Therapeutics, Inc. operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating ALGS should weigh these sector-specific dynamics alongside our model-derived fair values.
Is ALGS a Value Trap?
CirclFi's Value Trap algorithm assigns ALGS a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
10 of 13 models are active for Aligos Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Aligos Therapeutics, Inc.'s fundamental quality profile registers 4.1/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +298.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ALGS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ALGS's 10 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad